Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with tislelizumab for advanced osteosarcoma
ChiCTR2200065746Phase 2Not yet recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and tislelizumab in osteosarcoma (OS), sponsored by Beijing Jishuitan Hospital. Primary endpoint: 4-month progression-free survival rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
tucidinostattislelizumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2200065746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065746.